摘要
目的研究慢性阻塞性肺病急性加重期抗血小板聚积治疗对凝血系统、动脉血气分析、呼吸频率、心率的影响。方法慢性阻塞性肺病急性加重期患者93例,随机分为治疗组和对照组,治疗组除常规的抗感染、扩管、化痰、低流量吸氧等常规治疗外加丹奥静滴,对照组仅进行抗感染、扩管、化痰、低流量吸氧等常规治疗。比较治疗前和治疗后24h及72h两组凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(FIB)等凝血因素的变化及动脉血气分析、呼吸频率、心率等。结果1治疗组治疗前,24h,72h各指标比较均有显著性差异(P<0.05)。2对照组治疗前,24h各指标比较均无显著性差异(P>0.05);24h,72h比较,PT、APTT、FIB、PaO2、PaCO2及R有显著性差异(P<0.05)。3治疗组治疗24h、72h与对照组治疗24h、72h相比,各指标比较均有显著性差异(P<0.05)。结论抗血小板聚积治疗在单位时间内能提高动脉血氧分压,降低动脉血二氧化碳分压,改善呼吸频率等有明显疗效。
Objective： To study the effect of antiplatelet congestion on thromboxane system, arterial partial pressure of oxygen （PaO2）, arterial partial pressure of carbon d;oxide （PaCO2）, respiratory rates （R）, and heart rates （HR）in patients with chronic obstructive pulmonary disease exacerbation. Methods ：Ninety three patients with chronic obstructive pulmonary disease exacerbation were divided into treatment group and control group randomly. The controls were treated by anti-infection, dilating blood vessel, eliminating phlegm and inhaling low concentration oxygen. Those in the study group were treated with Ozagrel in addition to above routine treatment. We explored the difference in plasma prothombin time （PT）, activated partial thromboplastin time （APTT）, fibrinogen （FIB）, R, PaO2 and PaCO2 before therapy, 24 and 72 h after therapy. Results： There was significant difference in above index in treatment group between before therapy, 24 and 72 h after therapy（P〈0. 05）. There was no significant difference in above index in control group between before therapy and 24 h after therapy （P〉 0. 05）, but there was significant difference in APTT,FIB,PaO2, PaCO2 and R between 24 and 72 h after therapy （P〈0. 05）. There was significant difference in above index at 24 and 72 h after therapy between the treatment group and the control group （P〉 0. 05）. Conclusion： Antiplatelet congestion can significantly improve respiratory rates, PaO2 and PaCO2 in unit time.
出处
《陕西医学杂志》
CAS
北大核心
2007年第4期465-468,共4页
Shaanxi Medical Journal
关键词
肺疾病
慢性阻塞性/药物疗法
血小板聚集抑制剂/治疗应用
血气分析
Pulmonary disease, chronic obstructive/drug therapy Platelet aggregation inhibitors/therapentic use Blood gas analysis
